Daily close, T-120 (2/10/25) through T+5. Run-up high $179.1 on 6/25/25, low $119.49 on 2/17/25 (T-120 to T-1). FDA decision 7/28/25. Historical price action, not a forecast.
Positioning before the decision
On Jul 14, 2025, 14 days before the decision date, at-the-money options priced a move of ±11.2% through Aug 15, 2025 (the first listed expiry after the decision; ATM implied volatility 47%). The stock closed -2.0% at the first close across the decision and +4.2% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Was SKYTROFA (lonapegsomatropin-tcgd (ransCon hGH)) - (foresiGHt) approved by the FDA?
Yes. The FDA approved the application for SKYTROFA (lonapegsomatropin-tcgd (ransCon hGH)) - (foresiGHt) on July 28, 2025. The primary source is linked on this page.
What was SKYTROFA (lonapegsomatropin-tcgd (ransCon hGH)) - (foresiGHt) under FDA review for?
The application covered Growth Hormone Deficiency - adults. The FDA approved the application on July 28, 2025.
How did ASND stock react to the FDA decision?
On the decision day ASND moved -2.0%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.